SCHEMBL2009399

SCHEMBL2009399

CCCc1ccc2c(c1)C1(SCCS1)C(=O)N2CC(N)=O

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
TP53 P04637 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
MAPT P10636 3/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
THRB P10828 2/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
GAA P10253 1/20 0.33
S1PR1 P21453 1/20 0.33
ANPEP P15144 3/20 0.33
CYP26A1 O43174 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP26B1 Q9NR63 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008942 0.83 POLB (0.43) ALDH1A1TP53HDAC1MAPTLMNA
SCHEMBL2006817 0.78 ALDH1A1 (0.36) ALDH1A1TP53MAPTLMNASMN1; SMN2
SCHEMBL663087 0.71 HDAC1 (0.49) ALDH1A1TP53HDAC1HDAC8HDAC6
SCHEMBL29868620 0.71 HDAC1 (0.49) ALDH1A1TP53HDAC1HDAC8HDAC6
SCHEMBL2010777 0.69 L3MBTL1 (0.36) TP53SMN1; SMN2CYP3A4
SCHEMBL2006978 0.66 CYP1A2 (0.62) ALDH1A1TP53MAPTLMNASMN1; SMN2
SCHEMBL14000066 0.63 MAPT (0.46) ALDH1A1MAPTLMNASMN1; SMN2GAA
SCHEMBL2824115 0.61 ANPEP (0.48) ALDH1A1TP53HDAC1LMNAPTGDR2
SCHEMBL2823619 0.61 ANPEP (0.48) PTGDR2ANPEP
SCHEMBL660763 0.60 BRD4 (0.40) ALDH1A1HDAC1HDAC8HDAC6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US claimed
US-7964593-B2 Indolone-acetamide derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2011-06-21 US disclosed
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP disclosed
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2010-03-18 US disclosed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed
EP-1620399-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-02-01 EP disclosed
WO-2004087658-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses AANAT, TPH2, CYP1A2 ALDH1A1 308/4885TP53 4665/4885HDAC1 554/4885
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses AANAT, TPH2, CYP1A2 ALDH1A1 308/4885TP53 4665/4885HDAC1 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.